Technical Analysis for ARVN - Arvinas, Inc.

Grade Last Price % Change Price Change
grade C 24.175 1.19% 0.29
ARVN closed down 4.82 percent on Wednesday, July 17, 2019, on 87 percent of normal volume.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ARVN trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 1.19%
MACD Bearish Signal Line Cross Bearish 1.19%
NR7 Range Contraction -3.69%
Inside Day Range Contraction -3.69%
Down 3 Days in a Row Weakness -2.87%
Down 4 Days in a Row Weakness -2.87%
NR7 Range Contraction -3.30%
Down 3 Days in a Row Weakness -3.30%
Hammer Candlestick Bullish -3.65%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.65%

Older signals for ARVN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:
Profile
Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Biopharmaceutical Biology Diseases Genetics Metabolism
Is ARVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Jul 5 48 Biggest Movers From Wednesday
Jun 27 Will Arvinas Continue to Surge Higher?
Jun 26 Is Arvinas, Inc. (ARVN) A Good Stock To Buy?
Jun 25 Arvinas on go with early-stage study of ARV-471 in breast cancer
Jun 25 Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
Jun 20 Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference
Jun 12 Arvinas (ARVN) Investor Presentation - Slideshow
Jun 11 48 Stocks Moving In Tuesday's Mid-Day Session
Jun 6 Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Jun 5 Benzinga's Top Upgrades, Downgrades For June 5, 2019
See more ARVN news...
Indicators
Indicator Value
52 Week High 27.8
52 Week Low 10.19
Average Volume 221,672
200-Day Moving Average 18.6035
50-Day Moving Average 22.2986
20-Day Moving Average 23.9205
10-Day Moving Average 25.293
Average True Range 1.5242
ADX 19.71
+DI 24.5087
-DI 20.2272
Chandelier Exit (Long, 3 ATRs ) 23.2274
Chandelier Exit (Short, 3 ATRs ) 24.9426
Upper Bollinger Band 27.0087
Lower Bollinger Band 20.8323
Percent B (%b) 0.5
BandWidth 25.820531
MACD Line 0.9036
MACD Signal Line 0.9705
MACD Histogram -0.0669
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.62
Resistance 3 (R3) 26.83 26.12 26.17
Resistance 2 (R2) 26.12 25.43 26.02 26.01
Resistance 1 (R1) 25.01 25.00 24.66 24.80 25.86
Pivot Point 24.30 24.30 24.13 24.20 24.30
Support 1 (S1) 23.19 23.61 22.84 22.98 21.92
Support 2 (S2) 22.48 23.18 22.38 21.77
Support 3 (S3) 21.37 22.48 21.62
Support 4 (S4) 21.16